RxDoctor Payments Data

Autumn Dittenber, PA

Physician Assistant · Midland, MINPI 1013461581

Payments from drug & device makers

$2,713in general payments, 2019–2025

Across 64 payments — averaging $42.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$556
  • Otsuka America Pharmaceutical, Inc.$536
  • Lundbeck LLC$469
  • Johnson & Johnson$386
  • Axsome Therapeutics, Inc.$195
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$187
  • plus $383 from 6 others

What the payments were for

  • Food & beverage$2,49892%
  • Education$2158%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,713 in reported general payments places this provider in the 85th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$10,587
Medicare patients
43
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate110$350,980
Invega TrinzaPaliperidone Palmitate27$229,166
RexultiBrexpiprazole98$143,669
Abilify MaintenaAripiprazole46$128,433
VraylarCariprazine Hcl40$64,965
VivitrolNaltrexone Microspheres20$34,687
Paliperidone ErPaliperidone37$11,094
Clozapine90$7,785
TrintellixVortioxetine Hydrobromide16$7,651
Lurasidone Hcl20$7,260
Divalproex Sodium ErDivalproex Sodium168$5,851
Aripiprazole95$5,138
Atomoxetine Hcl29$2,243
Buspirone Hcl138$1,767
Haloperidol Decanoate38$1,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$386$580,146137 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$536$272,102144 claims
AbbVieVraylar$53$64,96540 claims
Alkermes, Inc.Vivitrol$104$34,68720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Midland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →